Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer-Reference-Cited by-同舟云学术

Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer

Published:2008-04 Issue:4 Volume:30 Page:775-784
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Danese Mark D.,Reyes Carolina,Northridge Kelly,Lubeck Deborah,Lin Chin-Yu,O'Connor Paula

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference15 articles.

1. Tyrosine kinase inhibitors and gemcitabine: New treatment options in pancreatic cancer?;Kleespies;Drug Resist Update,2006

2. Pancreatic adenocarcinoma,2006

3. Evaluation of erlotinib in advanced non-small cell lung cancer: Impact on the budget of a U.S. health insurance plan;Ramsey;J Manag Care Pharm,2006

4. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer;Hochster;Cancer,2006

5. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group;Moore;J Clin Oncol,2007

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study;Frontiers in Public Health;2021-11-05

2. Reporting Budget-Impact Analyses;Budget-Impact Analysis of Health Care Interventions;2017

3. A Methodological Review of US Budget-Impact Models for New Drugs;PharmacoEconomics;2016-06-22

4. Budget impact analysis of medicines: updated systematic review and implications;Expert Review of Pharmacoeconomics & Outcomes Research;2016-03-03

5. Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries;Journal of Cancer Policy;2016-03